Hello,

Welcome to our flagship newsletter, MarketBeat Daily Ratings.

We'll deliver the latest "Buy" and "Sell" ratings from Wall Street's top-rated analysts directly to your inbox each morning.

But first, we need you to do two quick things:

1. Hit reply, and send a simple "Yes." Just one word. This tells Google (and other emails providers) that you actually want to get our newsletter.

2. After that, this link to confirm your subscription. That will tell us that you received our welcome email and that we should start sending your daily report. 

Confirm your subscription here.

After you have completed these two steps, we would like to gift you a free copy of one of our most popular investing reports: 7 Stocks to Buy and Hold Forever. You can download the report with this link.

Thank you again for subscribing. We look forward to being an important part of your investing journey

Matthew Paulson
Founder and CEO, MarketBeat.

P.S. If you didn’t intend to subscribe, no problem—you can unsubscribe with this link.

(ARReply-161)

Accelerant’s Take-Private Deal Raises a Bigger Question for Insurance Stocks

Submitted by Nathan Reiff. Date Posted: 9/4/2026.

Accelerant Holdings (NYSE: ARX) came into view for investors in mid-August after its shares surged 43% in a single day. This type of share-price leap is often reserved for clinical-stage biotech firms announcing breakthrough results, for instance, not an unglamorous firm connecting specialty insurance risk across a network of capital providers. Investors, therefore, may underestimate Accelerant's performance potential.

Accelerant's major breakthrough on Aug. 13 resulted from two overlapping catalysts. First were the company's unusually strong Q2 2026 earnings results. Second, announced at the same time, was the firm's major reveal that it would be taken private by Thoma Bravo. Investors may be too late to maximize their gains on ARX stock, but the massive jump reveals important lessons about the specialty insurance industry that may pay off in other cases.

The First Major Driver: Extraordinary Earnings

Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad)

A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor.

This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.

Click here to learn this company's name for free today

Accelerant's earnings for the latest quarter were stellar, topping Wall Street expectations across multiple critical metrics. With nearly $357 million in revenue for the quarter, Accelerant improved this figure by about 63% year over year (YOY). Earnings per share (EPS) of 32 cents were more than double the 14 cents reported a year earlier. Both top- and bottom-line figures were significantly higher than Wall Street's already-optimistic expectations.

The magnitude of Accelerant's EPS beat, in particular, is a sign that profitability is expanding at a breakneck pace. In Q2 2025, net income attributable to common shareholders was $8.8 million; by the same quarter this year, it had climbed to nearly $79 million. Adjusted EBITDA also made major gains, demonstrating very healthy operating performance across multiple segments.

How Accelerant's Business Stands Out

Accelerant does not function like most insurance companies, which underwrite risk using their own balance sheets. Instead, it operates a specialty insurance exchange that connects capital providers, reinsurers, institutional investors and agents. Accelerant generates fee-based income from policies written through its exchange, allowing it to avoid taking on the insurance risk itself. This is crucial for the firm's margin growth: It means the company can expand without also taking on greater balance-sheet exposure.

The company is expanding its capacity through key partnerships with third-party-capitalized insurer WoodStar Reciprocal, among others. This should help Accelerant scale its fee revenue, which in turn may help the company distinguish itself further from industry peers. As Accelerant attracts more capital to its platform, more risk can also be taken on, generating larger volumes of fee income without increasing the company's own balance-sheet risk.

The Second Major Driver: A Private Equity Deal

Thoma Bravo plans to take Accelerant private in an all-cash transaction with an enterprise value of more than $4 billion, valuing the shares at $20.25 each. This represented a significant premium over Accelerant's pre-announcement price, but after the brief spike, the shares have stabilized just below that level.

While the Thoma Bravo deal may not present much of an investment opportunity now that it has been announced and investors have reacted accordingly, it does suggest that specialty insurance marketplace models may be undervalued elsewhere in the market. Thoma Bravo specializes in insurance technology platforms and is unlikely to have paid a premium approaching 50% without determining that the company was trading well below its true value.

Investors might view this as an opportunity to seek out other insurance companies operating outside the box and perhaps using Accelerant's low-capital, fee-heavy exchange model or something similar.

This Opportunity May Have Passed, But Others Could Await

ARX shares are currently trading slightly below the $20.25 take-private price as investors factor in deal-completion risk, regulatory timelines and other concerns. While some potential arbitrage opportunities remain, it seems unlikely that Accelerant will see another one-day gain like the one it experienced in August.

Investors may want to avoid wasting time on ARX and instead assess what about the company warranted such a premium from Thoma Bravo before seeking out those same qualities elsewhere. Two of Accelerant's competitors that may see a boost in investor attention following the announcement are Ryan Specialty Group Inc. (NYSE: RYAN) and Kinsale Capital Group Inc. (NYSE: KNSL). Although their share-price performance has not been as strong over the last month, both firms now operate in a market that has provided evidence of what a successful specialty insurance platform may be worth to investors.